Srihari Mahadev1, Monika Laszkowska1, Johan Sundström2, Magnus Björkholm3, Benjamin Lebwohl1, Peter H R Green1, Jonas F Ludvigsson4. 1. Celiac Disease Center, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York. 2. Department of Medical Sciences, Uppsala University, and Uppsala Clinical Research Center, Uppsala, Sweden. 3. Department of Medicine, Division of Hematology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden. 4. Celiac Disease Center, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Pediatrics, Örebro University Hospital, Örebro, Sweden; Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, Nottingham, United Kingdom. Electronic address: jonasludvigsson@yahoo.com.
Abstract
BACKGROUND & AIMS: Anemia is common in patients with celiac disease (CD) and a frequent mode of presentation. Guidelines recommend screening patients with iron-deficiency anemia (IDA) for CD. However, the reported prevalence of CD in patients with IDA varies. We performed a systematic review to determine the prevalence of biopsy-verified CD in patients with IDA. METHODS: We performed a systematic review of articles published in PubMed Medline or EMBASE through July 2017 for the term "celiac disease" combined with "anemia" or "iron deficiency." We used fixed-effects inverse variance-weighted models to measure the pooled prevalence of CD. Meta-regression was used to assess subgroup heterogeneity. RESULTS: We identified 18 studies composed of 2998 patients with IDA for inclusion in our analysis. Studies originated from the United Kingdom, United States, Italy, Turkey, Iran, and Israel. The crude unweighted prevalence of CD was 4.8% (n = 143). Using a weighted pooled analysis, we found a prevalence of biopsy-confirmed CD of 3.2% (95% confidence interval = 2.6-3.9) in patients with IDA. However, heterogeneity was high (I2 = 67.7%). The prevalence of CD was not significantly higher in studies with a mean participant age older or younger than 18 years or in studies with a mixed-sex vs female-predominant (≥60%) population. On meta-regression, year of publication, female proportion, age at CD testing, and prevalence in the general population were not associated with the prevalence of CD in patients with IDA. In the 8 studies fulfilling all our quality criteria, the pooled prevalence of CD was 5.5% (95% confidence interval = 4.1-6.9). CONCLUSIONS: In a systematic review and meta-analysis, we found that approximately 1 in 31 patients with IDA have histologic evidence of CD. This prevalence value justifies the practice of testing patients with IDA for CD.
BACKGROUND & AIMS:Anemia is common in patients with celiac disease (CD) and a frequent mode of presentation. Guidelines recommend screening patients with iron-deficiency anemia (IDA) for CD. However, the reported prevalence of CD in patients with IDA varies. We performed a systematic review to determine the prevalence of biopsy-verified CD in patients with IDA. METHODS: We performed a systematic review of articles published in PubMed Medline or EMBASE through July 2017 for the term "celiac disease" combined with "anemia" or "iron deficiency." We used fixed-effects inverse variance-weighted models to measure the pooled prevalence of CD. Meta-regression was used to assess subgroup heterogeneity. RESULTS: We identified 18 studies composed of 2998 patients with IDA for inclusion in our analysis. Studies originated from the United Kingdom, United States, Italy, Turkey, Iran, and Israel. The crude unweighted prevalence of CD was 4.8% (n = 143). Using a weighted pooled analysis, we found a prevalence of biopsy-confirmed CD of 3.2% (95% confidence interval = 2.6-3.9) in patients with IDA. However, heterogeneity was high (I2 = 67.7%). The prevalence of CD was not significantly higher in studies with a mean participant age older or younger than 18 years or in studies with a mixed-sex vs female-predominant (≥60%) population. On meta-regression, year of publication, female proportion, age at CD testing, and prevalence in the general population were not associated with the prevalence of CD in patients with IDA. In the 8 studies fulfilling all our quality criteria, the pooled prevalence of CD was 5.5% (95% confidence interval = 4.1-6.9). CONCLUSIONS: In a systematic review and meta-analysis, we found that approximately 1 in 31 patients with IDA have histologic evidence of CD. This prevalence value justifies the practice of testing patients with IDA for CD.
Authors: Kirsi Mustalahti; Carlo Catassi; Antti Reunanen; Elisabetta Fabiani; Margit Heier; Stan McMillan; Liam Murray; Marie-Helene Metzger; Maurizio Gasparin; Enzo Bravi; Markku Mäki Journal: Ann Med Date: 2010-12 Impact factor: 4.709
Authors: S Riestra; F Domínguez; E Fernández-Ruiz; E García-Riesco; R Nieto; E Fernández; L Rodrigo Journal: World J Gastroenterol Date: 2006-08-21 Impact factor: 5.742
Authors: S Husby; S Koletzko; I R Korponay-Szabó; M L Mearin; A Phillips; R Shamir; R Troncone; K Giersiepen; D Branski; C Catassi; M Lelgeman; M Mäki; C Ribes-Koninckx; A Ventura; K P Zimmer Journal: J Pediatr Gastroenterol Nutr Date: 2012-01 Impact factor: 2.839
Authors: L Vannella; M A Aloe Spiriti; E Di Giulio; E Lahner; V D Corleto; B Monarca; G Delle Fave; B Annibale Journal: Minerva Gastroenterol Dietol Date: 2010-12
Authors: Teresa Nestares; Rafael Martín-Masot; Ana Labella; Virginia A Aparicio; Marta Flor-Alemany; Magdalena López-Frías; José Maldonado Journal: Nutrients Date: 2020-03-21 Impact factor: 5.717
Authors: Rafael Martín-Masot; Maria Teresa Nestares; Javier Diaz-Castro; Inmaculada López-Aliaga; Maria Jose Muñoz Alférez; Jorge Moreno-Fernandez; José Maldonado Journal: Nutrients Date: 2019-10-23 Impact factor: 5.717